Similar to macrophages, microglia adopt diverse activation states and contribute to repair and tissue damage in multiple sclerosis. Using reverse transcriptionYquantitative polymerase chain reaction and immunohistochemistry, we show that in vitro M1-polarized (proinflammatory) human adult microglia express the distinctive markers CD74, CD40, CD86, and CCR7, whereas M2 (anti-inflammatory) microglia express mannose receptor and the anti-inflammatory cytokine CCL22. The expression of these markers was assessed in clusters of activated microglia in normal-appearing white matter (preactive lesions) and areas of remyelination, representing reparative multiple sclerosis lesions. We show that activated microglia in preactive and remyelinating lesions express CD74, CD40, CD86, and the M2 markers CCL22 and CD209, but not mannose receptor. To examine whether this intermediate microglia profile is static or dynamic and thus susceptible to changes in the microenvironment, we polarized microglia into M1 or M2 phenotype in vitro and then subsequently treated them with the opposing polarization regimen. These studies revealed that expression of CD40, CXCL10, and mannose receptor is dynamic and that microglia, like macrophages, can switch between M1 and M2 phenotypic profiles. Taken together, our data define the differential activation states of microglia during lesion development in multiple sclerosisYaffected CNS tissues and underscore the plasticity of human adult microglia in vitro.
INTRODUCTION
Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of the central nervous system (CNS) characterized by focal lesions of inflammation, axonal loss, gliosis, and demyelination. The lesions have been classified histopathologically according to the extent of myelin damage and the presence of activated microglia/macrophages (1) . Several white matter lesion types are described: active MS lesions typified by the presence of myelin in foamy microglia/macrophages; chronic active lesions with myelin-laden cells at the rim of the demyelinated area; and chronic inactive lesions with a hypocellular center and glial scar formation. Remyelination is frequently observed in MS brains, implying that regulation of inflammation and repair occurs even in patients with longstanding disease (2Y4). In addition to actively demyelinating lesions, clusters of active microglia have been observed in normal-appearing white matter (NAWM) (3, 4) . These clusters of microglia are not associated with myelin damage, leukocyte infiltration, or blood-brain barrier damage but rather with oligodendrocyte stress (5) . These so-called preactive lesions are thought to represent the first stage of lesion formation (4) . However, in view of the high numbers of preactive lesions, not all preactive lesions are thought to develop into actively demyelinating lesions (4) , suggesting intrinsic control of lesion formation.
Microglia are the primary innate immune cells in the immune-privileged CNS and play a key role in recruiting adaptive immune responses (6) . Microglia originate from the yolk sac and populate the CNS during early embryonic development (7) . Like macrophages, activated microglia produce a wide range of mediators to maintain brain homeostasis (6) . Their activation is strongly influenced by the environment, resulting in different activation states characterized by the production of different mediators and the expression of various markers (8Y12). Macrophages can be polarized in vitro into the M1 proinflammatory phenotype after stimulation with interferon-F (IFN-F) and lipopolysaccharide (LPS). The alternatively activated M2 phenotype (M2 macrophages) is further classified as M2a or wound-healing phenotype after exposure to interleukin (IL)-4 or IL-13, as M2b after exposure to immune complexes in combination with IL-1A or Toll-like receptor agonists, and as M2c after stimulation with IL-10 and glucocorticoids (9, 13, 14) . In both humans and mice, proinflammatory M1 macrophages express CD74, CD40, CD86, CD80, and the chemokine receptor CCR7 at high levels (9, 15Y17) . In contrast, the profile of IL-4Ystimulated cells includes the expression of mannose receptor (MR), and CD200R (11) . Different cytokines and chemokines are associated with these different activation states. For example, IL-1A, tumor necrosis factor (TNF), CCL2, and CXCL10 are associated with IFN-F/LPS activation, whereas CCL18, CCL22, and IL-10 are products of M2-polarized cells (18, 19) . Similar to macrophages, microglia are also susceptible to polarization (8, 9, 11) .
In inflammatory diseases of the CNS, M1 microglia are considered to be neurotoxic and damaging to oligodendrocytes, whereas M2 microglia fulfill immunosuppressive functions and promote repair (20) . This duality points to the role of microglia in demyelination, neuronal damage, and remyelination in MS and other CNS diseases. Studies in animal models of MS show inefficient remyelination after macrophage depletion caused by delayed myelin clearance and disturbed growth factor release (16, 21Y24) , both characteristic of M2 microglia/ macrophage. Recently, a study by Miron et al (25) described a switch from M1 to M2 cells coinciding with the initiation of remyelination, which is suggested to be essential for oligodendrocyte differentiation. In addition, reduced expression of arginase 1 (an M2 marker in mice) was observed during the relapse phase of experimental autoimmune encephalitis (EAE) (26) , which implies that M2 phagocytes play a role in regulating disease activity. However, despite studies in animal models and studies with human macrophages, the phenotype of adult human microglia and the expression of different microglia phenotypes in MS lesions have not been extensively studied.
Molecular changes in the NAWM of patients with MS indicate a proinflammatory role of microglia (27, 28) ; in contrast, however, Melief et al (12) reported that microglia derived from NAWM display an immune-suppressive profile. In previous studies using immunohistochemical approaches, however, Vogel et al (17) reported similar patterns of M1 and M2 markers expressed by microglia in NAWM and white matter from control subjects. M1 markers are observed in NAWM and in active, chronic active, and inactive white matter lesions, whereas M2 markers (CD163 and MR) are predominantly expressed by macrophages in the perivascular space (17, 29, 30) . In active MS lesions, M2 microglia/macrophages are abundant in the parenchyma, yet most of these cells also express M1 markers, indicating an intermediate activation state (17) .
We previously reported that preactive MS lesions are not associated with blood-brain barrier breakdown or leukocyte infiltration, suggesting that they are indeed composed of microglia rather than macrophages that have crossed the blood-brain barrier (3, 4) . In addition, microglia in preactive lesions express cytokines such as TNF, IL-10, and IL-23 (3, 31) ; however, a systematic analysis of classical M1 or M2 microglia phenotypes in these early lesions was not performed. Therefore, we examined whether changes in the balance of M1 and M2 microglia phenotypes in preactive lesions might explain why some preactive lesions may develop into active lesions whereas others resolve. Such expression patterns were compared with microglia in remyelinating lesions, in which microglia are proposed to play a repair-promoting role.
We first examined whether human M1 and M2 microglia can be distinguished by phenotypic markers by exposing them to IFN-F/LPS or IL-4, thereby promoting either activation state (9, 11, 12) . Using the markers identified, we show here that preactive and remyelinating lesions are not composed of purely M1 or M2 microglia but rather express M1 and M2 markers by the same cell. To examine whether the cells expressing both M1 and M2 markers reflect a dynamic population, we polarized microglia into M1 and M2 populations and subsequently treated them with the alternative polarization regimen. Taken together, our data define the differential activation states of microglia during lesion development and regression in MS and underscore the plasticity of human adult microglia in vitro, thereby supporting emerging evidence that the activation states of macrophages and probably microglia are a continuum, with M1 and M2 phenotypes on either end of this spectrum.
MATERIALS AND METHODS

Autopsy Material
Postmortem human brain tissue was obtained according to the protocol of The Netherlands Brain Bank (Amsterdam, The Netherlands; coordinator, Dr I. Huitinga), in agreement with the Medical Ethical Committee of the VU University Medical Center (Amsterdam, The Netherlands). All patients and controls provided a written informed consent form for autopsy and use of their brain tissue and clinical details for research purposes. Patient information is summarized in Table 1 .
Cell Isolation and Differentiation: Human Macrophages
Pure macrophage cultures were obtained as described by Vogel et al (17, 32) . Briefly, a Ficoll density gradient (Lymphoprep i ; Axis-Shield, Oslo, Norway) was used to isolate peripheral blood mononuclear cells from heparinized healthy donor blood. Monocytes were sorted using anti-CD14 magnetic beads according to the manufacturer's protocol (Miltenyi Biotec, Leiden, The Netherlands) and cultured in uncoated 6-well plates (Greiner Bio-One, Alphen a/d Rijn, The Netherlands) at a density of 2 Â 10 6 cells/mL. Culture wells were filled with Dulbecco modified Eagle medium (Invitrogen, Paisley, United Kingdom) supplemented with 5% (vol/vol) heat-inactivated normal human serum (Bio Whittaker, East Rutherford, NJ), 1% (vol/vol) penicillin-streptomycin-glutamine (Invitrogen), and 25 ng/mL of granulocyte-macrophage colonystimulating factor (Immunotools, Friesoythe, Germany). Monocytes were cultured in a 5% CO 2 Yhumidified incubator at 37-C for 5 to 7 days to mature them into macrophages. 3 [Merck], pH 7.4) for 10 minutes at 4-C. Cells were rinsed and resuspended in culture medium (Dulbecco modified Eagle medium/Ham nutrient mixture F10 1:1 supplemented with 10% heat-inactivated fetal bovine serum, 1% penicillin-streptomycin-glutamine, and 25 ng/mL of granulocyte-macrophage colony-stimulating factor) and cultured under similar culture conditions as the macrophages.
Human Microglia Isolation
After 7 days, microglia were polarized into M1 phenotype by priming with 1 Â 10 3 U/mL of recombinant human IFN-F (U-Cytech, Utrecht, The Netherlands) for 24 hours, followed by addition of 10 ng/mL of Escherichia coli LPS (LPS-EB Ultrapure; InvivoGen, San Diego, CA) to the medium for 24 hours. To induce M2 microglia, we activated the cells with 10 ng/mL of IL-4 (Immunotools) for 48 hours. Untreated cells are referred to as M0.
Macrophage and Microglia Morphology
To examine the morphology of macrophages and microglia, we cultured cells in 4-well glass slides (Lab-Tek, Rochester, NY) under the same conditions as described previously. Unstained cells were examined by light microscopy, and adherent cells were photographed with a Leica DMIL microscope (Leica, Rijswijk, The Netherlands).
Flow Cytometry
Expression of CD68, CD45, and CD11b in cultured macrophages and microglia was analyzed by flow cytometry. Cells were harvested and fixed with 4% buffered paraformaldehyde. Subsequently, the cells were incubated with antibodies to CD11b (1:50, clone ICRF 44; eBioscience, Huissen, The Netherlands), CD45 (1:100, biotin-labeled, clone HI30; eBioscience), or CD68 (1:100, clone EBM11; Dako, Glostrup, Denmark) in PBS containing 0.1% saponin and 0.1% BSA for 1 hour at room temperature (RT). After washing, fluorescently labeled secondary antibodiesVgoat anti-mouse Alexa488 (1:400; Invitrogen) and streptavidin Alexa647 (1:400; Invitrogen)V were allowed to bind primary antibodies for 30 minutes at RT. Isotype-matched antibodies: mouse IgG1 negative control (AbD Serotec, Kidlington, Oxford, United Kingdom) and mouse IgG negative control biotin (AbD Serotec) were used to determine specific staining.
Flow cytometry analysis was performed using FACS Calibur (Becton Dickinson, Erembodegem, Belgium) combined with Cellquest Pro software (Becton Dickinson) and FlowJo software version 9.4.0 for Microsoft (Tree Star, San Carlos, CA), allowing the use of mean fluorescence intensity to compare macrophages and microglia. Data were collected from 3 separate experiments performed in duplicate. Data are presented as mean T SE.
Messenger RNA Isolation and Real-Time Quantitative Polymerase Chain Reaction
To compare the gene expression of markers in microglia phenotypes, we isolated messenger RNA (mRNA) using the mRNA Capture Kit (Roche Applied Science, Almere, The Netherlands) according to the manufacturer's protocol. Subsequently, reverse transcription was performed with the Reverse Transcription System (Promega, Madison, WI) following the manufacturer's instructions, using PTC 200 DNA Engine gradient cycler (MJ Research, St Bruno, Quebec, CA). Complementary DNA was diluted 3 times in primer mix consisting of forward and reverse primers diluted in sybrgreen (SSO advanced Sybr green supermix; Biorad, Veenendaal, The Netherlands) and DNase/RNase-free water (Invitrogen). Polymerase chain reaction (PCR) amplification was performed with the Viia7 Real-Time PCR System (Applied Biosystems, Bleiswijk, The Netherlands). Expression of selected genes was normalized to the reference gene EF1> (elongation factor 1>), and relative expression was calculated as E jC T target gene =E jC T reference gene (expressed in arbitrary units). Efficiency of primer pairs per run was determined using LinRegPCR software 11.0 (33) .
Primer sequences and individual annealing temperatures are provided in Table 2 . Replacement of sample by water per primer in every run and routinely performed melting curves and gel electrophoresis of PCR products were used to determine the specificity of PCR (data not shown). Material was collected from 6 donors; experiments were performed in triplicate. Data are presented as mean T SE.
Immunohistochemistry of Cultured Microglia
Microglia cultured in 8-well glass slides (Lab-Tek) and stimulated as described previously were fixed with 4% paraformaldehyde for 10 minutes at RT. To decrease nonspecific background, we incubated the cells with blocking buffered (PBS containing 0.1% cold fish skin gelatin [Sigma], 0.25% Triton X-100 [Merck], 1% BSA [Roche], 0.05% Tween 20 [Merck] , and 2% normal goat serum [Dako]) for 1 hour at RT. After washing, the primary antibody (Table 3) was added overnight at RT.
To visualize primary antibody binding, we incubated the cells with either Alexa Fluor488Ylabeled (1:400; Invitrogen) or Alexa Fluor594Ylabeled (1:400; Invitrogen) secondary antibodies for 2 hours at RT. Between incubation steps, cells were rinsed repeatedly in washing buffer composed of blocking buffer without normal goat serum.
Nuclei were stained with 4 ¶,6-diamidino-2-phenylindole (Invitrogen) in 0.2 Kg/mL of PBS for 10 minutes, and glass slides were overlaid with a coverslip mounted with FluorPreservei (Millipore, Billerica, MA). Isotype-matched antibodies were used as controls (Table 3) .
Images were taken using Leica DFC 450C (Leica LAS AF software), and the fluorescence intensity of 7 cells per condition per donor (n = 3) was analyzed by 2 independent observers using ImageJ software (34), as described by Gavet and Pines (35) .
Enzyme-Linked Immunosorbent Assay
Quantification of CCL22 and CXCL10 in microglial culture supernatants was performed using commercially available enzyme-linked immunosorbent assay (ELISA) kits according to the manufacturer's instructions (Sigma). These cytokines characterize either M1 (CXCL10) or M2 (CCL22) activation states (36) .
Briefly, supernatants from polarized microglia were transferred into antibody-coated wells, incubated overnight, and washed. Subsequently, biotinylated antibody was added for 1 hour at RT, followed by the addition of streptavidinY horseradish peroxidase solution to form biotin-streptavidin complexes. The addition of 3,3 ¶,5,5 ¶-tetramethybenzidine reagent resulted in a colorigenic reaction, which was halted by a ''stop'' solution after 30 minutes. Absorbance was measured at 450 nm, and protein concentration in the samples was calculated according to standard curves. Material was collected from 6 donors; experiments were performed in triplicate. Data are presented as mean T SE.
Immunohistochemistry of MS Lesions and Control Brain Tissue
Lesions were selected based on histochemical Luxol fast blue stain, according to the protocol described by Kooi et al (37) , and single immunohistochemical stains directed to the myelin proteolipid protein (PLP) and major histocompatibility complex class II (MHC-II) to identify activated microglia. Proteolipid protein and MHC-II were stained according to a previously described protocol using Envision-HRP (Dako) and 3,3 ¶-diaminobenzidine (Dako) as detection method (17) .
For colocalization studies of MHC-II and different M1/M2 markers in control tissue and MS lesions, air-dried 5-Km-thick cryosections were fixed with acetone for 10 minutes and rinsed in PBS. Endogenous peroxidase was quenched by incubating sections in PBS containing 0.3% H 2 O 2 for 30 minutes. Next, slides were preincubated for 1 hour with blocking buffer consisting of 2% normal human serum and 5% normal goat serum in PBS. Subsequently, slides were incubated overnight at RT with primary antibodies to the M1 or M2 marker (Table 3 ) diluted in blocking buffer. After washing, sections were incubated with alkaline phosphatase (1:50; AbD Serotec) or biotin-labeled (1:500; Jackson ImmunoResearch, West Grove, PA) secondary antibody diluted in Antibody Diluenti (Immunologic, Duiven, The Netherlands) for 1 hour at RT. Using the latter, we subsequently incubated the sections with streptavidinYalkaline phosphatase (1:4000; Roche) for 1 hour to form complexes labeled with biotinYstreptavidinYalkaline phosphatase. The sections were then rinsed in Tris-buffered saline and stained with liquid permanent red (Dako). Thereafter, slides were incubated with antibodies to MHC-II (Table 3) CD74  GACGAGAACGGCAACTATCTG  GTTGGGGAAGACACACCAGC  58  CD40  CCTTGGACAAGCTGTGAGAC  AGATGATGGGGATCACCACC  60  CD86  CTGCTCATCTATACACGGTTACC  GGAAACGTCGTACAGTTCTGTG  61  CD80  TCGTATGTGCCCTCGTCAGAT  GGCCCGAGTACAAGAACCG  58  CCR7  TTCCTGTGTGGTTTTACCGC  CTTGACACAGGCATACCTGG  62  MR  AAATGTTGAAGGGACGTGGC  CTCCAAAACCCAGAAGACGC  60  CD200R  GAGCAATGGCACAGTGACTGTT  GTGGCAGGTCACGGTAGACA  60  IL-1A  CCAAACCTCTTCGAGGCACAA  TACTTCTGCCATGGCTGCTTCA  60  CCL2  CAGCCAGATGCAATCAATGCC  TGGAATCCTGAACCCACTTCT  62  TNF  CACCGGAACGACATGGAGA  TCCAGGCGACAAAAGGGTTA  60  CXCL10  GTGGCATTCAAGGAGTACCTC  TGATGGCCTTCGATTCTGGATT 
Plasticity of M1 and M2 Microglia
To study the plasticity of adult human M1 and M2 microglia, we polarized microglia after 5 days of culture to obtain M1 or M2 phenotypes as described previously. After rinsing, the cells were treated for a further 48 hours with alternative stimuli (i.e. M1 microglia with IL-4 for 48 hours). M2 microglia were first primed with recombinant human IFN-F for 24 hours then incubated with IFN-F and LPS for 24 hours. As control, a medium in culture wells containing unstimulated M0 microglia was replaced with fresh medium after 48 hours. The so-called ''switched'' cells were compared to cells harvested after only polarization into M1 and M2.
Statistical Analysis
Data were statistically analyzed using GraphPad Prism software (GraphPad Software, San Diego, CA). To compare the 3 different phenotypes, we performed Kruskal-Wallis 1-way analysis of variance. Pairwise comparison was performed using Mann-Whitney U test. A probability value (p) of 0.05 or less was considered to be significant.
RESULTS
Morphology of Macrophages and Microglia
Cultured microglia and monocyte-derived macrophages were analyzed for morphology, size, and granularity. In contrast to macrophages that showed a variety of cell morphologies (spherical and elongated cells), microglia adopted a more bipolar morphology (Figs. 1A, B) . Evaluation of forward scatter and sideward scatter plots revealed a population of macrophages homogenous in size and granularity (Fig. 1A ). Microglia were distinguished by smaller size and higher granularity, demonstrated by decreased forward scatter (size) and increased sideward scatter (granularity) (Fig. 1B) .
Purity of Macrophage and Microglia Isolation and Marker Expression
The purity of microglia and macrophages was determined by CD68 expression, which revealed that both microglia and macrophage cultures contained more than 95% CD68-positive cells. CD68-positive microglia were discriminated from CD68-positive macrophages by CD11b and CD45 expression. Macrophages were identified as CD11b low and CD45 high , whereas microglia showed CD11b high and CD45 low expression, as quantified by mean fluorescence intensity (Fig. 1C) .
Gene Expression Profiling of Polarized Microglia
Human microglia were cultured for 7 days and either unstimulated (M0) or polarized into M1 (IFN-F and LPS) or M2 (IL-4) phenotype. The expression of a panel of marker transcripts known to be differentially expressed under either proinflammatory or anti-inflammatory conditions was examined. Figure 2 shows the transcript expression levels of markers relative to the housekeeper gene EF1> for the 3 microglia phenotypes. Experiments were performed with microglia isolated from 6 different subjects per marker. Although microglia were obtained from patients with neurologic diseases other than MS (Table 1) , similar consistent responses were obtained after polarization between individual patients (data not shown). Gene expression of CD74, CD40, CD86, CD80, and CCR7 (markers associated with a proinflammatory phenotype) was significantly upregulated under M1 stimulation conditions compared to M0 and M2. In contrast, CD200R and MR (related to a M2 phenotype) were significantly more highly expressed in M2 microglia (A). The proinflammatory cytokines IL-1A, TNF, and CXCL10 were significantly increased in M1 microglia, whereas CCL22 was expressed higher in IL4Ystimulated (M2) microglia (B). Error bars represent SE (n = 6 for each condition). * p e 0.05, ** p e 0.01, *** p e 0.001 (pairwise comparison, Mann-Whitney U test). AU, arbitrary units (E jCT target gene =E jCT reference gene ).
The markers CD74, CD40, CD86, CD80, and CCR7 were significantly increased in M1 microglia versus nonstimulated (M0) and IL-4 (M2)Ystimulated cells ( Fig. 2A) . In contrast, gene expression of MR and CD200R was significantly increased under M2-promoting conditions as compared to M1-favoring conditions. However, expression levels of MR in M2 microglia were not significantly different from those of M0 microglia, and absolute levels of expression of CD200R were low ( Fig. 2A) . For gene expression of cytokine and chemokines, IL-1A, TNF, and CXCL10 were identified as distinguishing markers for M1-polarized microglia (Fig. 2B) . The immune regulatory cytokine CCL22 was significantly increased in both M1 and M2 microglia, albeit 4 times more strongly upon M2 polarization (p e 0.05). The 3 phenotypes did not show any significant differences in the expression of CCL18 and IL-10 ( Fig. 2B ).
Protein Expression of M1 and M2 Markers in Polarized Microglia in Vitro
To investigate the protein expression of the selected panel of genes, we performed immunohistochemistry on cultured primary adult human M0, M1, or M2 microglia. Fluorescence intensity of the macrophage lineage marker CD68 showed stable expression in all phenotypes (Figure, Supplemental Digital Content 1, http://links.lww.com/NEN/A681). Similar to transcript profiles, protein expression of M1 and M2 markers revealed different profiles for the 3 microglia phenotypes (Fig. 3A) . Quantification of protein expression using ImageJ showed significantly increased expression of CD74, CD40, CD86, CCR7, TNF, and CXCL10 (p e 0.01) in M1-polarized cells compared to M0 and M2 microglia (Fig. 3B) . Such quantification showed that CD80 expression in M1 cells was not significantly different from that in M2-polarized cells. Under M2 polarization conditions, MR and CCL22 were significantly increased (p e 0.01). Yet, the staining intensity of CCL22 was already significantly higher in IFN-F/LPSYstimulated versus unstimulated cells; however, the intensity was increased 4-fold under M2 conditions. CD200R did not show a significant difference between M1 and M2 phenotypes. Representative immunostaining of the expression of all markers is illustrated in Figure, Supplemental Digital Content 2, http://links.lww.com/NEN/A682. The functional effect of polarization was assessed by determining the production of CXCL10 and CCL22 (as representative M1 and M2 markers, respectively) in supernatants using ELISA. It was observed that supernatants of M1-polarized microglia contained significantly higher levels of CXCL10 than supernatants of M0 and M2 cells (p e 0.01; Fig. 4) . In contrast, CCL22 levels were significantly increased (p e 0.01) in supernatants of M2-polarized cells versus supernatants of M0 and M1 microglia.
In summary, the consistently distinguishing markers of M1-polarized microglia in vitro were CD74, CD40, CD86, CCR7, TNF, and CXCL10, whereas MR and CCL22 were the defining characteristics of M2-polarized microglia.
Expression of M1 and M2 Markers in Preactive Lesions
Preactive lesions were defined as clusters of activated microglia expressing high levels of MHC-II in NAWM (Fig. 5A) . To determine whether microglia clusters represent a lesion stage preceding active lesion formation or whether they represent reparative lesions, we performed immunohistochemistry for M1 and M2 markers on 25 to 40 preactive lesions present in 13 blocks from 7 patients with MS compared to white matter obtained from 3 healthy control subjects. Microglia clusters were stained for coexpression of MHC-II (to define the lesion) and the markers CD74, CD40, CD86, and CCR7 (which are highly expressed by M1 microglia in vitro; Figs. 2, 3) , or for coexpression of MR and CCL22, characteristic of the M2 phenotype.
In all preactive lesions, approximately 80% of the cells expressed MHC-II. All MHC-IIYpositive cells coexpressed IBA1 (ionized calcium-binding adapter molecule 1), and no cells in preactive lesions expressed only IBA1, indicating that all microglia were activated (data not shown). Evaluation of the percentage of MHC-IIYpositive cells expressing selected microglia markers revealed that most MHC-IIYpositive cells expressed the M1 markers CD74 (mean T SE, 81% T 2.9% ), CD40 (mean T SE, 73% T 5.7%), and CD86 (mean T SE, 90% T 3.1%), whereas lower numbers were positive for CCR7 (mean T SE, 13.5% T 1.6%) (Fig. 5B) . For M2 markers, CCL22 was expressed by most MHC-IIYpositive cells in preactive lesions (mean T SE, 90% T 1.9%), whereas in contrast to our finding that the M2 marker MR is expressed in active lesions (17) , only a small number of MHCIIYpositive cells in preactive lesions expressed MR (mean T SE, 1.8% T 0.56%) (Fig. 5B) . Examination of control white matter revealed that microglia also weakly expressed CCL22, although less intensely than that observed in NAWM in MS (data not shown). As an additional M2 marker, as shown by Durafourt et al (9), we examined the expression of CD209 (DC-SIGN) on microglia in preactive lesions. This revealed a similar expression pattern as CCL22 (data not shown).
In summary, most MHC-IIYpositive cells in preactive lesions express M1 (CD40, CD74, and CD86) and M2 (CCL22 and CD209) markers, whereas CCR7-positive and MR-positive microglia were observed only rarely in preactive lesions. Using these markers, we only observed 1 type of preactive lesion.
Expression of M1 and M2 Microglia Markers in Remyelinating Lesions
Remyelinating lesions were identified by areas containing a paucity of myelin, as identified by reduced Luxol fast blue and PLP stains, in which activated ramified microglia, but no foamy macrophages and lymphocytes, were present (Fig. 6 ). To examine whether microglia in these lesions are indeed reparative as would be expected, we evaluated the expression of M1 and M2 markers identified from in vitro studies of 9 tissue blocks from 4 different donors. CD40, CD86, and CCL22 were consistently expressed by ramified MHC-IIYpositive microglia in remyelinated lesions (Fig. 6) . Expression of CD40 was also observed in endothelial cells, whereas CCL22 was exclusively expressed by activated ramified microglia and not by perivascular macrophages. In contrast, MR-positive cells were not observed in the tissue parenchyma but were restricted to perivascular spaces around blood vessels within remyelinated areas (Fig. 6) .
In summary, we show for the first time that most of the activated microglia in remyelinating lesions in MS differentially express the M1 markers CD40 and CD86 and the M2 marker CCL22. In addition, in these lesions, macrophages in perivascular spaces express MR but not CCL22, where expression is restricted to MHC-IIYpositive parenchymal cells.
Microglia Reveal Plasticity in Vitro
To examine whether microglia expressing both M1 and M2 markers in vivo reflect a single cell population that can adopt different polarization profiles, we studied the dynamics of microglia polarization in vitro. After 5 days of culture, microglia were first polarized to obtain M1 and M2 populations; thereafter, cells were treated with the alternative polarization regimen for another 2 days. The switched cells were compared to cells that were only polarized into M1 and M2. As shown in Figure 7 , there was a general trend in downregulation of M1 markers and upregulation of M2 markers at the gene transcript level after the polarization method was switched from M1 to M2; however, only CXCL10 showed significant differences (p e 0.05). Stimulating microglia with IFN-F/LPS (M1) after IL-4 (M2) stimulation resulted in a significant increase in CD40 and CXCL10 (p e 0.05) and a significant decrease in MR and CCL22 (p e 0.05). These data indicate that polarization of human adult microglia is dynamic; cells are able to switch between proinflammatory and anti-inflammatory phenotypes.
DISCUSSION
To further examine the contribution of microglia to MS lesion formation, we compared the activation status of microglia in preactive lesions and areas of remyelination. Given that critical differences in the morphology, marker expression, and functionality of polarized cells are observed between murine and human microglia (20, 38Y40), we polarized human adult microglia. We and others have previously identified proinflammatory (M1) and anti-inflammatory (M2) markers expressed in polarized peripheral human macrophages and mouse microglia (8, 16Y18) . To determine whether these markers are applicable to primary human microglia, we first analyzed the gene transcript and protein expression profiles of M1-and M2-polarized primary microglia derived from human adult CNS white matter. The present studies confirm and extend previous studies on human adult microglia (9, 11, 12) , reveal new M1 and M2 markers, and show that (like macrophages) differentially activated microglia remain highly susceptible to changes in the microenvironment. Translation of clues from in vitro studies to MS tissues revealed that microglia in preactive and remyelinating lesions exhibit an intermediate phenotype expressing CD74, CD40, and CD86 (characteristic of M1-polarized microglia) and the immunoregulatory markers CCL22 and CD209. Microglia in these lesions do not express MR and CCR7, in contrast to active MS lesions. Together, these findings reveal that microglia in preactive MS lesions resemble reparative remyelinating lesions rather than actively demyelinating lesions. Microglia phenotypes can be induced by a range of factors, including IFN-F, LPS, IL-1A, IL-4, IL-10, IL-13, dexamethasone, and pathogen-and damage-associated molecular patterns (14, 41) . In vitro, LPS and IL-4 are the strongest mediators to polarize M1 and M2 primary mouse microglia and human macrophages (42) . Here, we confirm that these conditions are also applicable to adult human microglia to induce M1 and M2 microglia (8, 9, 14, 43) . In contrast to macrophages that show distinct morphologic differences between the 2 phenotypes (44), we did not observe such differences between M1 and M2 adult human microglia, in agreement with observations made by Durafourt et al (9) . Under M1 conditions, human adult microglia upregulate the markers CD74, CD40, CD86, CD80, and CCR7 at the gene transcript level compared to unstimulated and M2 cells. Immunohistochemical analysis revealed that CD74, CD40, CD86, and CCR7, but not CD80, were distinctive M1 markers. In contrast to the study by Durafourt et al (9) , who reported high numbers of CD80-and CCR7-positive cells by fluorescence-activated cell sorting, we examined the intensity of expression compared to unstimulated M0 microglia.
The proinflammatory molecule CD74 functions as a chaperone of MHC-II during antigen presentation and induces different signaling cascades that lead to activation of nuclear factor JB and mitogen-activated protein kinase cascade (20, 45) . In EAE, CD74 is expressed by microglia and macrophages, and blocking such interaction ameliorates EAE, indicating a proinflammatory role (46) . Higher levels of CD74 in monocytes were observed in patients with MS compared to controls (47) . Similarly, CD74 expression in M1 microglia was increased, in line with previously reported data on porcine macrophages (48) . Interferon-F and LPS also induce expression of the costimulatory proteins CD40 and CD86 in human macrophages (17, 49, 50) ; we now show that this is also applicable to primary adult human microglia. By contrast, microglia stimulated with IL-4 expressed higher gene transcripts of MR and CD200R compared to IFN-F/LPSY stimulated cells; however, protein levels of CD200R were not significantly different between the 3 phenotypes. Although our studies show that MR was a distinguishing marker for M2-polarized microglia, this finding is in contrast to that of Melief et al (11) , who used freshly isolated human microglia. The lack of expression of MR reported by Melief et al (11) could be attributable to the use of a rapid isolation method that might have induced an inflammatory activation state, whereas in our studies, microglia were isolated and brought to resting state before polarization. Our apprach is similar to the study by Durafourt et al (9) in which only a slight upregulation of MR under M2 polarization conditions was observed.
To fulfill their dual role, microglia produce a broad range of chemokines and cytokines. In the present study, we showed that CCL22 is increased in M2 microglia, whereas TNF and CXCL10 are more highly expressed by M1 microglia. In contrast to our findings, Melief et al (11) showed a relative unresponsiveness of human microglia to LPS and IFN-F. This can be explained by the concept of priming, in which previously stimulated cells evoke an excessive inflammatory response to a secondary stimulus (51, 52) . Such priming may well precondition microglia, thereby affecting their capability to respond to a secondary challenge. Although human microglia were primed with IFN-F for 24 hours prior to stimulation with LPS in the present study, Melief et al (11) treated microglia with a cocktail of IFN-F and LPS immediately after isolation. This protocol may activate a different profile indicating that, in vivo, the functional properties of microglia are influenced by environmental signals, depending on the duration and combination of stimuli.
In brain tissues of patients with MS, microglia are exposed to a plethora of ligands and stimuli, whose composition, concentration, and exposure can vary with time. For example, NAWM contains proinflammatory and antiinflammatory cytokines, including IL-1A and IL-10, which are known to influence microglial phenotypes (28) . In line with studies in rodents, such conditioning may affect the capabilities of microglia to respond to a later challenge (39) . The human microglia used in the present study were isolated from patients with a variety of neurologic disorders. As discussed previously, for priming, plasticity, and molecular memory (52, 53) , this may well influence the proinflammatory and anti-inflammatory phenotypes in vitro. However, detailed analysis did not reveal differences between the expression of selected markers in individual patients. This is in line with studies by Bsibsi et al (31, 54) that used the small heat shock protein HSPB5 as stimulus, indicating that apparent in vivo priming of microglia does not impact on responses in vitro.
Clues from in vitro studies were translated to MS tissues, revealing that microglia in preactive and remyelinating lesions highly express CD74, CD40, and CD86 (characteristic of M1-polarized microglia) and the immunoregulatory cytokines CCL22 and CD209. Thus, similar to our studies on active lesions, microglia in preactive lesions do not have static M1 or M2 activation status but an intermediate phenotype.
However, in contrast to active MS lesions, microglia do not express MR and rarely express CCR7. Thus, despite the finding that M2 microglia express MR in vitro, such expression in vivo is generally restricted to foamy macrophages and perivascular macrophages, which are absent in preactive lesions (3, 17, 55) . Similarly, abundant CCR7 expression is detected in myeloid cells in actively demyelinating MS lesions, whereas preactive lesions contained only low numbers of CCR7-positive cells and control tissues lacked CCR7 expression (56) . In EAE, CCR7 is upregulated during relapse and is decreased at remission, suggesting that CCR7 plays an important role during the inflammatory damaging phase of the disease by recruiting subpopulations of T cells and antigenpresenting dendritic cells (57) . That CCR7 was not characteristic of preactive lesions may explain the absence of T cells in these lesions. On the other hand, CD86 showed an almost complete overlap with MHC-II expression in preactive lesions, in contrast to NAWM, suggesting that microglia in early lesion formation are in a vigilant state (17) . This is supported by the finding that microglia in preactive lesions express TNF (3). Yet, most microglia in preactive lesions expressed CD209 and the anti-inflammatory cytokine CCL22. CD209 has been proposed to play a key role in immune regulation in the CNS (58) . Expression of CD209 in foamy macrophages, perivascular macrophages, and microglia in nonlesion white and gray matter of patients with MS has previously been demonstrated (58Y61). Here, we now show the expression of CD209 in microglia in preactive lesions, supporting the idea of an intermediate microglia phenotype in these lesions.
The cytokine CCL22 is important for the recruitment of dendritic cells, T H 2, and regulatory T cells (62) . In the present study, we show that microglia in control tissue weakly express CCL22; however, in NAWM in brains of MS patients, such expression is increased, whereas this is even more abundant in preactive and remyelinating lesions. Although the exact role of CCL22 in MS lesion development remains to be established, this expression in lesions in the CNS might explain why levels of CCL22 are higher in the cerebrospinal fluid of patients with MS than in control subjects (63) .
Microglia in preactive lesions are associated with the expression of the heat shock protein HSPB5 (>B-crystallin), IL-23, and IL-10, suggesting a level of immune control in these lesions (3, 5, 32, 54) . Although IL-4 has been described in MS lesions (64, 65) , it is not detected by immunohistochemistry in preactive lesions (3) . This might explain why microglia in preactive MS lesions do not adopt the typical M2 phenotype associated with IL-4 stimulation. IL-4Ystimulated microglia have been suggested to aid tissue repair via induction of neurogenesis and oligodendrogenesis of adult neural progenitor cells in mice (18, 66) . Therefore, this phenotype might play a more prominent role in remyelination. A recent study by Miron et al (25) revealed that M2 microglia expressing MR stimulate remyelination by enhancing oligodendrocyte differentiation. However, as discussed previously, MRpositive cells were restricted to the perivascular space. In mice, M2 cells are abundant in demyelinated areas 10 days after induction of lysolecithin-induced lesions, where they aid differentiation of oligodendrocyte progenitors into myelinforming oligodendrocytes. However, in this model at 21 days after lesion formation, M2 cells were not detectable, whereas M1 cells dominate these areas (25) . This time-dependent change could explain the absence of MR in the parenchyma in remyelinated areas of patients with MS in our cohort.
Accumulating data show that differentially activated macrophages do not adopt a static activation state but remain highly susceptible to changes in the microenvironment (41) . Here, we present for the first time that, like macrophages, human microglia easily transform their expression profile in vitro. These data suggest that, also in vivo, the versatility of microglia may be strongly influenced not only by environmental stimuli but also by the combination of stimuli and temporal aspects of exposure.
We hypothesized that expression of M1 markers in preactive lesions would promote the development of active lesions, whereas resolving lesions would express M2 markers. However, our data reveal that microglia express an intermediate activation status in all preactive and remyelinating lesions that differs from microglia profiles in actively demyelinating lesions. This supports accumulating evidence that the activation status of macrophages and microglia is very dynamic and occurs as a continuum, with the proinflammatory (M1) and antiinflammatory (M2) phenotypes on either end of this spectrum (14) , and this can be influenced by both systemic signals and local environmental signals. In MS, examination of local signals, such as the MS-relevant protein HSPB5 in the presence of IFN-F (54), may better distinguish pathogenic and regulatory microglia phenotypes.
